MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases
MiNK Therapeutics, Inc. recently announced the presentation of data from MiNK-215, an investigational IL-15 armored fibroblast activation protein (FAP) targeting CAR-iNKT cell therapy, at the American Association for Cancer Research (AACR) Meeting in San Diego, CA.
“MiNK-215 represents a novel cellular therapeutic to overcome the limitations of immune checkpoint blockade therapy. The data presented at AACR demonstrate MiNK-215’s potential to effectively combat colorectal liver metastases, offering hope for patients who have exhausted conventional treatment options,” said Dr. Jennifer Buell, President and Chief Executive Officer at MiNK. “Furthermore, these results accentuate MiNK-215’s versatility and synergistic potential when paired with immunotherapies such as Agenus’ botensilimab and balstilimab. This collaboration holds promise in bolstering the anti-tumor response, particularly in the formidable realm of microsatellite stable colorectal cancer.”
Liver mets have limited the efficacy of immunotherapy in patients with mismatch repair proficient/microsatellite-stable (pMMR/MSS) colorectal cancer (CRC). MiNK’s innovative iNKT cell therapy, MiNK-215, has shown the ability to remodel the immunosuppressive tumor microenvironment within the liver. Human organoid models of CRC with liver metastases revealed that MiNK-215 exhibits potent anti-tumor activity through multiple mechanisms that include:
- Tumor stroma remodeling: MiNK-215 effectively remodels the tumor stroma, the supportive tissue surrounding the tumor to create a more favorable environment for immune cell infiltration and activity.
- Immune activation: By reprogramming the tumor microenvironment (TME), MiNK-215 reduces the presence of immune-suppressive FAP expressing stellate cells and CXCL-12 expressing cells.
- Enhanced tumor killing: MiNK-215 recruits tumor-reactive T cells, pivotal in mounting an effective immune response against the tumor, ultimately leading to enhanced tumor eradication.
Data presented at the conference is available to view in the publications section of the MiNK website https://minktherapeutics.com/publications/.
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/>
Total Page Views: 381
